Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

767 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results of adjuvant interferon study in WHO melanoma programme.
Cascinelli N, Bufalino R, Morabito A, Mackie R. Cascinelli N, et al. Among authors: morabito a. Lancet. 1994 Apr 9;343(8902):913-4. doi: 10.1016/s0140-6736(94)90030-2. Lancet. 1994. PMID: 7908370 Clinical Trial. No abstract available.
Melanoma and pregnancy.
MacKie RM, Bufalino R, Morabito A, Sutherland C, Cascinelli N. MacKie RM, et al. Among authors: morabito a. Lancet. 1991 Jun 29;337(8757):1607. doi: 10.1016/0140-6736(91)93303-q. Lancet. 1991. PMID: 1675732 No abstract available.
A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, Bufalino R, Cascinelli N, Cocconi G, Durand J, De Marsillac J, Ikonopisov RL, Kiss B, Lejeune F, MacKie R, Madej G, Mulder H, Mechl Z, Milton GW, Morabito A, Peter H, Priario J, Paul E, Rumke P, Sertoli R, Tomin R. Veronesi U, et al. Among authors: morabito a. N Engl J Med. 1982 Oct 7;307(15):913-6. doi: 10.1056/NEJM198210073071503. N Engl J Med. 1982. PMID: 7050717 Clinical Trial.
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
Sertoli MR, Queirolo P, Bajetta E, Del Vecchio M, Comella G, Barduagni L, Bernengo MG, Vecchio S, Criscuolo D, Bufalino R, Morabito A, Cascinelli N. Sertoli MR, et al. Among authors: morabito a. Melanoma Res. 1999 Oct;9(5):503-9. doi: 10.1097/00008390-199910000-00010. Melanoma Res. 1999. PMID: 10596917 Clinical Trial.
767 results